Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 10/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 10/20 | 0.51 |
| ▸ | WDR5 | P61964 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21485570 | 1.00 | CSNK2A2 (0.51) | CSNK2A2CSNK2A1WDR5EGLN1CNR1 | |
| SCHEMBL22927081 | 0.93 | CSNK2A2 (0.44) | CSNK2A2CSNK2A1WDR5EGLN1CNR1 | |
| SCHEMBL21481906 | 0.93 | CSNK2A2 (0.44) | CSNK2A2CSNK2A1WDR5EGLN1CNR1 | |
| SCHEMBL31203566 | 0.90 | CSNK2A2 (0.41) | CSNK2A2CSNK2A1WDR5CNR1CNR2 | |
| SCHEMBL21458238 | 0.90 | CSNK2A2 (0.41) | CSNK2A2CSNK2A1WDR5CNR1CNR2 | |
| SCHEMBL21485584 | 0.90 | CSNK2A2 (0.41) | CSNK2A2CSNK2A1WDR5CNR1CNR2 | |
| SCHEMBL24991871 | 0.87 | CSNK2A2 (0.46) | CSNK2A2CSNK2A1EGLN1CNR1CNR2 | |
| SCHEMBL21481784 | 0.87 | CSNK2A2 (0.52) | CSNK2A2CSNK2A1EGLN1CNR2HPGDS | |
| SCHEMBL21481907 | 0.87 | EGLN1 (0.39) | EGLN1CNR1CNR2 | |
| SCHEMBL31203172 | 0.85 | WDR5 (0.42) | CSNK2A2CSNK2A1WDR5CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230045612-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20210024491-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | CSNK2A2 574/4885CSNK2A1 711/4885WDR5 3222/4885 |
| US-20230045612-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | CSNK2A2 574/4885CSNK2A1 711/4885WDR5 3222/4885 |
| US-20210024491-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | CSNK2A2 574/4885CSNK2A1 711/4885WDR5 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.